Myeloproliferative Neoplasms News

In this video, Aaron T. Gerds, MD, MS, discussed the backstory behind a study presented at ASCO Annual Meeting, examining the effect of the BET inhibitor pelabresib on patients with essential thrombocythemia.

In this video, Aaron T. Gerds, MD, MS, discussed the backstory behind a study he presented at ASCO Annual Meeting, examining the effect of luspatercept on patients with myelofibrosis suffering from anemia.

CHICAGO — In this video, Andrew Tiu, MD, discussed results from a study regarding the link between Agent Orange and myeloproliferative neoplasms, which he presented at ASCO Annual Meeting.

CHICAGO — In this video, Maneesh Jain, MD, discussed the backstory behind a study he co-authored regarding the link between Agent Orange and myeloproliferative neoplasms, presented at ASCO Annual Meeting.

New prior authorization policies appeared associated with about a 2-week delay in oral oncology drug prescription fills, according to study results presented during ASCO Annual Meeting.

Treatment with luspatercept vs. epoetin alfa nearly doubled the number of patients with lower-risk myelodysplastic syndrome who no longer required red blood cell transfusions for anemia, results of the phase 3 COMMANDS trial showed.

An oncology financial navigation intervention decreased financial toxicity among patients with blood cancers and their caregivers, according to study results.

The FDA approved omidubicel-onlv, a donor cord blood-based cell therapy, to accelerate neutrophil recovery and reduce the risk for infection among patients with hematologic malignancies undergoing stem cell transplantation.

HHS on Monday released the National Cancer Plan, which includes eight goals and strategies to prevent cancer, reduce related mortality and improve the lives of people living with the disease.

Delaying antibiotic treatment beyond 1 hour from developing neutropenic fever did not affect OS among hospitalized patients with cancer, results from a retrospective study showed.